Small Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: An Overview

The epidermal growth factor receptor (EGFR) has been identified as a relevant target for treatment of solid tumors, as it is involved in regulating cellular functions important in the proliferation and survival of cancer cells, is commonly expressed in a range of tumors, and high expression is often...

Full description

Saved in:
Bibliographic Details
Published in:Journal of chemotherapy (Florence) 2004-11, Vol.16 (sup4), p.36-40
Main Authors: Normanno, N., Maiello, M.R., Mancino, M., De luca, A.
Format: Article
Language:English
Subjects:
Biological Availability
Clinical Trials, Phase I as Topic
Clinical Trials, Phase III as Topic
Dose-Response Relationship, Drug
Drug Administration Schedule
Enzyme Inhibitors - pharmacology
Enzyme Inhibitors - therapeutic use
Epidermal growth factor
Female
Humans
Male
Molecular Weight
Neoplasms - drug therapy
Neoplasms - pathology
Prognosis
Protein-Tyrosine Kinases - antagonists & inhibitors
Protein-Tyrosine Kinases - therapeutic use
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - metabolism
Treatment Outcome
tyrosine kinase inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The epidermal growth factor receptor (EGFR) has been identified as a relevant target for treatment of solid tumors, as it is involved in regulating cellular functions important in the proliferation and survival of cancer cells, is commonly expressed in a range of tumors, and high expression is often related to poor prognosis. Some of the most advanced target based agents in clinical development are the EGFR tyrosine kinase inhibitors (EGFR-TKIs). This brief review summarizes the results of phase II monotherapy trials of EGFR TKIs in cancer patients. The molecular mechanisms involved in regulating the sensitivity/resistance of tumor cells to EGFR-TKIs are also discussed.
ISSN:1120-009X
1973-9478
DOI:10.1179/joc.2004.16.Supplement-1.36